BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 26163437)

  • 1. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.
    Wu X; Huang J; Liu L; Li H; Li P; Zhang J; Xie L
    Medicine (Baltimore); 2016 Sep; 95(39):e4926. PubMed ID: 27684830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Ma BBY; Kam MKM; Leung SF; Hui EP; King AD; Chan SL; Mo F; Loong H; Yu BKH; Ahuja A; Chan ATC
    Ann Oncol; 2012 May; 23(5):1287-1292. PubMed ID: 21948811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
    Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.
    Hui EP; Ma BB; Leung SF; King AD; Mo F; Kam MK; Yu BK; Chiu SK; Kwan WH; Ho R; Chan I; Ahuja AT; Zee BC; Chan AT
    J Clin Oncol; 2009 Jan; 27(2):242-9. PubMed ID: 19064973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
    Zhang L; Shan GP; Li P; Cheng PJ
    Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
    Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.
    Zhang X; Du L; Zhao F; Wang Q; Yang S; Ma L
    Int J Biol Sci; 2016; 12(4):446-53. PubMed ID: 27019628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
    Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
    Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials.
    Kong L; Hu C; Niu X; Zhang Y; Guo Y; Tham IW; Lu JJ
    Cancer; 2013 Dec; 119(23):4111-8. PubMed ID: 24037893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
    Chen CY; Lu TX; Zhao C; Lu LX; Han F; Sun Y
    Ai Zheng; 2007 Apr; 26(4):398-402. PubMed ID: 17430660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.
    Liu YJ; Zhu GP; Guan XY
    Oral Oncol; 2012 Jun; 48(6):554-9. PubMed ID: 22289637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy.
    Chen C; Chen T; Huang C; Wang J; Fei Z
    Medicine (Baltimore); 2017 Nov; 96(44):e8434. PubMed ID: 29095283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy study of weekly cisplatin with concurrent intensity-modulated radiation therapy for nasopharyngeal carcinoma: preliminary results.
    Lu H; Chen J; Huang B; Cheng J; Peng L; Hao Y; Liao C; Mo Y; Wu D; Qin J
    Oral Oncol; 2010 Oct; 46(10):743-7. PubMed ID: 20833579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.